You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 基石藥業(2616.HK)漲逾8% 腫瘤創新藥獲批速度超預期
格隆匯 05-25 11:06
格隆匯5月25日丨基石藥業(2616.HK)漲逾8%,暫錄4連陽,區間漲幅達25%,現報13.1港元,高見13.22港元創逾一年半新高,總市值155億港元。5月22日,基石藥業在上海舉辦首屆腫瘤精準治療論壇暨泰吉華中國上市會。基石藥業首席醫學官楊建新表示,腫瘤創新藥獲批速度之迅速超出了公司的預期。從基石藥業和國外籤合同到遞交新藥上市申請(NDA),再到批下來只用了不到3年的時間。就在本月初,在獲批僅一個月左右時間,泰吉華就已經在北京大學腫瘤醫院、北京大學人民醫院、上海交通大學醫學院附屬仁濟醫院等近三十家醫院同步開出首批處方單,並正式面向全國多個省市的五十多家院內和院外藥房供藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account